In its Phase I trial in patients with advanced solid tumors, MRX34 demonstrated target engagement and tumor-suppressive activity (with downregulation of BCL2, MET, MYC) at tolerated doses, but the trial was ultimately discontinued due to immune-mediated adverse events [68,69]. The gene discussed is BCL2; the disease is neoplasm.